Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: Promise and concern

Journal of AAPOS

Volumn 13, Issue 4, 2009, Pages 329-331

  Avery, Robert L ^a  

^a California Retina Consultants and Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLON CANCER; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; LOW DRUG DOSE; OPHTHALMOLOGY; PEDIATRICS; PRIORITY JOURNAL; RETINA EDEMA; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; RETINA VEIN OCCLUSION; RETROLENTAL FIBROPLASIA; SUBRETINAL NEOVASCULARIZATION;

ADOLESCENT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; RETINAL DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68349123734     PISSN: 10918531     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaapos.2009.06.003     Document Type: Editorial

References (24)

1. Gunther J.B., and Altaweel M.M. Bevacizumab (avastin) for the treatment of ocular disease. Surv Ophthalmol 54 (2009) 372-400
2. Ciulla T.A., and Rosenfeld P.J. Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 20 (2009) 158-165
3. Ciulla T.A., and Rosenfeld P.J. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr Opin Ophthalmol 20 (2009) 166-174
4. Gaudreault J., Fei D., Rusit J., Suboc P., and Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46 (2005) 726-733
5. Pieramici D.J., and Avery R.L. Ranibizumab: Treatment in patients with neovascular age-related macular degeneration. Exp Opin Biol Ther 6 (2006) 1237-1245
6. Dafer R.M., Schneck M., Friberg T.R., and Jay W.M. Intravitreal ranibizumab and bevacizumab: A review of risk. Semin Ophthalmol 22 (2007) 201-204
7. Ueta T., Yanagi Y., Tamaki Y., and Yamaguchi T. Cerebrovascular accidents in ranibizumab. Ophthalmology 116 (2009) 362
8. Alexander S.L., Linde-Zwirble W.T., Werther W., Depperschmidt E.E., Wilson L.J., Palanki R., et al. Annual rates of arterial thromboembolic events in Medicare neovascular age-related macular degeneration patients. Ophthalmology 114 (2007) 2174-2178
9. Avastin Drug Warning. 2005. Available at http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM164188.pdf. Accessed June 13, 2009.
10. Wu L., Martínez-Castellanos M.A., Quiroz-Mercado H., Arevalo J.F., Berrocal M.H., Farah M.E., et al. Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): Results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246 (2008) 81-87
11. Cakir M., Cekiç O., and Yilmaz O.F. Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats disease. J AAPOS 12 (2008) 309-311
12. Cakir M., Cekiç O., and Yilmaz O.F. Intravitreal bevacizumab and triamcinolone treatment for choroidal neovascularization in Best disease. J AAPOS 13 (2009) 94-96
13. Cakir M., Cekiç O., and Yilmaz O.F. Intravitreal bevacizumab for idiopathic choroidal neovascularization. J AAPOS 13 (2009) 296-298
14. Mintz-Hittner H.A., and Best L.M. Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Pediatr 21 (2009) 182-187
15. al-Dhibi H., and Khan A. Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema. J AAPOS 13 (2009) 400-402
16. Avery R.L., Pearlman J., Pieramici D.J., Rabena M.D., Castellarin A.A., Nasir M.A., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113 (2006) 1695-1705
17. Aiello L.P. Targeting intraocular neovascularization and edema-One drop at a time. N Engl J Med 359 (2008) 967-969
18. Wu Z., and Sadda S.R. Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: A case report. Ann Acad Med Singapore 37 (2008) 591-593
19. Scartozzi R., Chao J.R., Walsh A.C., and Eliott D. Bilateral improvement of persistent diffuse diabetic macular oedema after unilateral intravitreal bevacizumab (Avastin) injection. Eye 23 (2009) 1229
20. Velez-Montoya R., Fromow-Guerra J., Burgos O., Landers III M.B., Morales-Catón V., and Quiroz-Mercado H. The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: A pilot study. Retina 29 (2009) 20-26
21. ®) for neovascular age-related macular degeneration (AMD): 2-year results for fellow eyes with neovascular AMD (MARINA, ANCHOR). Presented at: Annual Meeting of the American Society of Retina Specialists. Palm Springs (2007)
22. Bakri S.J., Snyder M.R., Reid J.M., Pulido J.S., and Singh R.J. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114 (2007) 855-859
23. Nomoto H., Shiraga F., Kuno N., Kimura E., Fujii S., Shinomiya K., et al. Pharmacokinetics of bevacizumab after topical, subconjunctival and intravitreal administration in rabbits. [epub ahead of print, March 25]. Invest Ophthalmol Vis Sci (2009)
24. Bakri S.J., Snyder M.R., Reid J.M., Pulido J.S., Ezzat M.K., and Singh R.J. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114 (2007) 2179-2182